文献速递冠心病血脂与心血管预防

ISCHEMIA试验:药物依从性与健康结局的关联

Association of Medication Adherence With Health Outcomes in the ISCHEMIA Trial.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

ISCHEMIA试验随机分配慢性冠心病患者接受指南导向药物治疗联合或不联合血管造影与血运重建,评估基线药物依从性与12个月健康状态结局的关联。结果显示27.8%参与者基线不依从,依从性与两种治疗策略下12个月SAQ-7汇总评分更高相关,且无治疗交互作用。

要点

  • 超过1/4的慢性冠心病患者报告药物不依从。
  • 依从性与12个月健康状态评分更高相关,无论保守或侵入策略。
  • 改善药物依从性的策略对慢性冠心病患者健康结局至关重要。

核心结论

  • 超过1/4的慢性冠心病患者报告药物不依从,且不依从与基线和12个月时更差的健康状态相关,无论保守或侵入治疗策略。

研究设计与样本

  • ISCHEMIA试验随机分配慢性冠心病患者至指南导向药物治疗联合或不联合血管造影与血运重建。
  • 采用改良4条目Morisky-Green-Levine依从性量表在随机化时评估自我报告的服药行为,将参与者分类为依从或不依从。
  • 共纳入4480名随机参与者,其中1245名(27.8%)基线不依从。
  • 使用贝叶斯比例优势模型评估依从性与结局的关联,包括治疗组(保守 vs 侵入)的交互作用。

主要发现

  • 不依从参与者在保守组基线SAQ-7汇总评分为72.9 ± 19.3 vs 依从组75.6 ± 18.4,侵入组为71.0 ± 19.8 vs 74.2 ± 18.7。
  • 调整分析中,依从性与12个月SAQ-7汇总评分更高相关:保守治疗平均差异1.6(95%可信区间:0.3-2.9),侵入管理平均差异1.9(95%可信区间:0.8-3.1)。
  • 依从性与治疗组之间无交互作用。

临床怎么用

  • 临床应关注慢性冠心病患者的药物依从性,无论采取保守或侵入治疗策略。
  • 改善药物依从性的策略可能有助于提升慢性冠心病患者的健康状态结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) trial randomized participants with chronic coronary disease (CCD) to guideline-directed medical therapy with or without angiography and revascularization. The study examined the association of nonadherence with health status outcomes. OBJECTIVES: The study sought to compare 12-month health status outcomes of adherent and nonadherent participants with CCD with an a priori hypothesis that nonadherent patients would have better health status if randomized to invasive management. METHODS: Self-reported medication-taking behavior was assessed at randomization with a modified 4-item Morisky-Green-Levine Adherence Scale, and participants were classified as adherent or nonadherent. Twelve-month health status was assessed with the 7-item Seattle Angina Questionnaire (SAQ-7) summary score (SS), which ranges from 0 to 100 (higher score = better). The association of adherence with outcomes was evaluated using Bayesian proportional odds models, including an interaction by study arm (conservative vs invasive). RESULTS: Among 4,480 randomized participants, 1,245 (27.8%) were nonadherent at baseline. Nonadherent participants had worse baseline SAQ-7 SS in both conservative (72.9 ± 19.3 vs 75.6 ± 18.4) and invasive (71.0 ± 19.8 vs 74.2 ± 18.7) arms. In adjusted analyses, adherence was associated with higher 12-month SAQ-7 SS in both treatment groups (mean difference in SAQ-7 SS with conservative treatment = 1.6 [95% credible interval: 0.3-2.9] vs with invasive management = 1.9 [95% credible interval: 0.8-3.1]), with no interaction by treatment. CONCLUSIONS: More than 1 in 4 participants reported medication nonadherence, which was associated with worse health status in both conservative and invasive treatment strategies at baseline and 12 months. Strategies to improve medication adherence are needed to improve health status outcomes in CCD, regardless of treatment strategy. (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches [ISCHEMIA]; NCT01471522).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Garcia RA, Spertus JA, Benton MC, et al. Association of Medication Adherence With Health Outcomes in the ISCHEMIA Trial. J Am Coll Cardiol. 2022. PMID: 35981820. doi:10.1016/j.jacc.2022.05.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。